Vaccines-2013 - OMICS Group

Recommendations

Info

Ahtisham-Ul-Haq, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAEffectiveness of BCG vaccination in preventing tuberculosisAhtisham-Ul-HaqService Institue of Medical Sciences, PakistanCommon lower respiratory tract infections include tuberculosis, asthma and chronic obstructive pulmonary disease (COPD).World Health Organization (WHO) defined tuberculosis as an infectious disease caused by Mycobacterium tuberculosiswhich most commonly affects lungs. With increase in prevalence, tuberculosis (TB) is now the second only to AcquiredImmuno-Deficiency Syndrome (AIDS) as the greatest killer worldwide due to a single infectious agent. Bacille Calmette Guérin(BCG) vaccination has been developed against tuberculosis to decrease the mortality from this disease. Although BCG is notcommonly inoculated in America, it is routinely given to infants and children in countries where TB is prevalent. However, casesof tuberculosis have been identified even after inoculation of BCG vaccine. This study was conducted at tuberculosis and asthmaclinic of Children Hospital Lahore from January 2012 to December 2012. All those children were included in the study who metthe selection criteria. Out of 500 children half, 250 (50%) were male while remaining 250 (50%) were females. 227 (45.4%) werediagnosed as having TB on the basis of PPASC. 389 (77.8 %) were vaccinated while remaining 111 (22.2 %) were not vaccinated.Out of 227 children with diagnosis of TB, 91 (39.9%) were male while 136 (59.9%) were females. Out of 389 vaccinated children,132 (33.9%) were diagnosed as having TB while out of 111 non-vaccinated children 95 (85.6%) got TB. Results of the studyindicate that although vaccination with BCG decreases the prevalence of TB however, it is not 100% effective in combating withtuberculosis.BiographyAhtisham-Ul-Haq completed his M.B.B.S at the age of 25 years from Allama Iqbal Medical College. He did his M.P.H. from Institute Of Public Healthin 2004 and is currently enrolled in M.Phil. in Community Medicine. Currently he is working as additional medical superintendant at a well-reputedtertiary care hospital. He has presented his research work at various national and international forums.auhaq31@gmail.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 82
Teena Mohan et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAImmunomodulatory functions of defensins, innate molecules, as mucosal adjuvant with thepeptide antigens of HIV-1 at the mucosal surfacesTeena Mohan and D. N. RaoDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, IndiaIntroduction: The mechanisms of resistance to HIV infection in the human oral cavity are incompletely understood whilesalivary components have been implicated in protection. There are growing evidences that human defensin peptides originatingin the oral epithelial cells may be playing an important role in the prevention of HIV infection.Methodology: We have synthesized HIV and Defensin peptides and their corresponding analogues by making some modificationsin the natural sequence. We have done Anti HIV, Anti-microbial and other characteristic study of defensins to prove them active.Then, immunized theses formulations in Outbred and Two different Inbred mice (H 2b , H 2d ) through IN route using Microsphereas delivery vehicle. We have studied Humoral Response of HIV peptides with and without Defensins by estimating antibody levels(IgG/IgA) in the serum as well as in lung, intestinal, vaginal and rectal washes till day 120. For cell mediated immune response,peptide specific T cell proliferation and cytokine/chemokine levels were studied in the cells isolated from the three differentmucosal sites i.e. spleen, lamina propria and peyer’s patches of the primed mice. Simultaneously, we have done Cytolytic activityanalysis, by estimating IFN-γ/Perforin secretion by CD4+ also through FACS, which was checked by IFN- γ/Perforin secretion.Result & Discussion: The HIV peptides alone in microsphere showed low peptide specific response of peak titre in sera anddifferent washes while the presence of defensins increased significantly this titre both in sera (1,02,400-4,09,600) as well as inwashes (800-12,800) (p
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32: 111 th OMICS Group Conference3 rd I
Page 33 and 34: Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36: Nikolai Petrovsky, J Vaccines Vacci
Page 39 and 40: Robert E. Sievers et al., J Vaccine
Page 41 and 42: Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44: Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46: Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48: Diane Longo et al., J Vaccines Vacc
Page 49 and 50: Track 33: Novel Approaches in Desig
Page 51 and 52: Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54: Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56: A. Bennett Jenson et al., J Vaccine
Page 57 and 58: Milan Raska et al., J Vaccines Vacc
Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81: Kaissar Tabynov et al., J Vaccines
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134:
Ghaffarifar F et al., J Vaccines Va
Page 135 and 136:
Mathan Periasamy et al., J Vaccines
Page 137 and 138:
Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140:
Samuel Teshome, J Vaccines Vaccin 2
Page 141 and 142:
Page 143 and 144:
Birhanu Hurisa et al., J Vaccines V
Page 145 and 146:
Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148:
Belachew Etana et al., J Vaccines V
Page 149 and 150:
Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152:
Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154:
Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156:
Sandeepkumar R. Chauhan et al., J V
Page 157 and 158:
Veronica Rainone et al., J Vaccines
Page 159 and 160:
Page 159
Page 161 and 162:
Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?